CY1994A - Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase inhibitor - Google Patents

Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase inhibitor Download PDF

Info

Publication number: CY1994A
Authority: CY; Cyprus
Prior art keywords: sodium; carbonate; composition; pharmaceutical composition; hmg
Prior art date: 1991-12-12

Application number

CY199497A

Other languages

English (en)

Original Assignee

Sandoz Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-12

Filing date

1997-09-05

Publication date

1997-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36808687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-09-05 Application filed by Sandoz Ltd filed Critical Sandoz Ltd

1997-09-05 Publication of CY1994A publication Critical patent/CY1994A/en

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims description 10
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
239000000203 mixture Substances 0.000 claims description 102
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 38
150000001875 compounds Chemical class 0.000 claims description 37
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 31
-1 HMG-CoA compound Chemical class 0.000 claims description 24
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 21
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 21
239000008108 microcrystalline cellulose Substances 0.000 claims description 21
229940016286 microcrystalline cellulose Drugs 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
238000000034 method Methods 0.000 claims description 20
229910000019 calcium carbonate Inorganic materials 0.000 claims description 19
239000008186 active pharmaceutical agent Substances 0.000 claims description 16
229940088679 drug related substance Drugs 0.000 claims description 16
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 15
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 13
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 12
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 10
239000007864 aqueous solution Substances 0.000 claims description 9
239000006185 dispersion Substances 0.000 claims description 8
229960000868 fluvastatin sodium Drugs 0.000 claims description 8
229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
230000000087 stabilizing effect Effects 0.000 claims description 6
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 5
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 5
150000001768 cations Chemical class 0.000 claims description 3
239000008203 oral pharmaceutical composition Substances 0.000 claims 2
150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
239000007892 solid unit dosage form Substances 0.000 claims 1
159000000000 sodium salts Chemical class 0.000 description 32
229960003765 fluvastatin Drugs 0.000 description 23
239000003814 drug Substances 0.000 description 19
229940079593 drug Drugs 0.000 description 17
239000003826 tablet Substances 0.000 description 17
239000000945 filler Substances 0.000 description 13
239000002552 dosage form Substances 0.000 description 12
239000002245 particle Substances 0.000 description 12
239000000126 substance Substances 0.000 description 11
239000007888 film coating Substances 0.000 description 10
238000009501 film coating Methods 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229920000881 Modified starch Polymers 0.000 description 8
238000003860 storage Methods 0.000 description 8
150000005323 carbonate salts Chemical class 0.000 description 7
238000001035 drying Methods 0.000 description 7
238000009505 enteric coating Methods 0.000 description 7
239000002702 enteric coating Substances 0.000 description 7
239000008187 granular material Substances 0.000 description 7
239000000314 lubricant Substances 0.000 description 6
238000002156 mixing Methods 0.000 description 6
238000005550 wet granulation Methods 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
239000000463 material Substances 0.000 description 5
235000002639 sodium chloride Nutrition 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
239000008188 pellet Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
125000000714 pyrimidinyl group Chemical group 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000001665 trituration Methods 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
125000001041 indolyl group Chemical group 0.000 description 3
239000008101 lactose Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229960003975 potassium Drugs 0.000 description 3
238000012545 processing Methods 0.000 description 3
125000000168 pyrrolyl group Chemical group 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000000181 anti-adherent effect Effects 0.000 description 2
239000003911 antiadherent Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
239000004744 fabric Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
208000020346 hyperlipoproteinemia Diseases 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229910052806 inorganic carbonate Inorganic materials 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
239000003605 opacifier Substances 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
239000008213 purified water Substances 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229940032147 starch Drugs 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical group C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical group C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
MMTXSCWTVRMIIY-UHFFFAOYSA-N 3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)CC(O)CC(O)C=C MMTXSCWTVRMIIY-UHFFFAOYSA-N 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010034960 Photophobia Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
206010057040 Temperature intolerance Diseases 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940024548 aluminum oxide Drugs 0.000 description 1
RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
239000002585 base Substances 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000011162 core material Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
229960002380 dibutyl phthalate Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000007905 drug manufacturing Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
YURNCBVQZBJDAJ-UHFFFAOYSA-N heptenoic acid group Chemical group C(C=CCCCC)(=O)O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
208000013469 light sensitivity Diseases 0.000 description 1
QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
239000002370 magnesium bicarbonate Substances 0.000 description 1
235000014824 magnesium bicarbonate Nutrition 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229910000406 trisodium phosphate Inorganic materials 0.000 description 1
235000019801 trisodium phosphate Nutrition 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY199497A 1991-12-12 1997-09-05 Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase inhibitor CY1994A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80566791A	1991-12-12	1991-12-12
CN93100650A CN1041794C (zh)	1991-12-12	1993-01-30	含有一种β－羟基－β－甲基戊二酸单酰辅酶A还原酶抑制剂的稳定的药物组合物

Publications (1)

Publication Number	Publication Date
CY1994A true CY1994A (en)	1997-09-05

Family

ID=36808687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY199497A CY1994A (en)	1991-12-12	1997-09-05	Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase inhibitor

Country Status (31)

Country	Link
US (1)	US5356896A (fr)
EP (1)	EP0547000B1 (fr)
JP (1)	JP2774037B2 (fr)
KR (1)	KR100253824B1 (fr)
CN (1)	CN1041794C (fr)
AT (1)	AT401870B (fr)
AU (1)	AU661075B2 (fr)
CA (1)	CA2085037C (fr)
CH (1)	CH684309A5 (fr)
CY (1)	CY1994A (fr)
CZ (1)	CZ287776B6 (fr)
DE (1)	DE4240430B4 (fr)
DK (1)	DK0547000T3 (fr)
ES (1)	ES2142819T3 (fr)
FI (1)	FI114284B (fr)
FR (1)	FR2684876B1 (fr)
GB (1)	GB2262229B (fr)
GR (1)	GR3032929T3 (fr)
HK (1)	HK25597A (fr)
HU (2)	HU217629B (fr)
IL (1)	IL104041A (fr)
IT (1)	IT1256698B (fr)
LU (1)	LU88201A1 (fr)
MX (1)	MX9207152A (fr)
NO (1)	NO302099B1 (fr)
NZ (1)	NZ245421A (fr)
PT (1)	PT547000E (fr)
RO (1)	RO111542B1 (fr)
RU (1)	RU2121835C1 (fr)
SK (1)	SK281710B6 (fr)
ZA (1)	ZA929642B (fr)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6300361B1 (en) *	1990-07-25	2001-10-09	Novartis Ag	Stabilized pharmaceutical compositions comprising acid donors
DE4243279A1 (de) *	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
US5399356A (en) *	1994-03-24	1995-03-21	The Procter & Gamble Company	Process for making solid dose forms containing bismuth
RU2152209C1 (ru) *	1994-05-13	2000-07-10	Егис Гиогисзергуар Р.Т.	Гемфиброзил-содержащие фармацевтические композиции
CA2229605A1 (fr)	1995-08-17	1997-02-27	The Regents Of The University Of California	Genes et proteines regulant la synthese du cholesterol
ES2183023T3 (es) *	1995-12-22	2003-03-16	Kowa Co	Composicion farmaceutica estabilizada con un agente basico.
RU2188013C2 (ru) *	1996-04-05	2002-08-27	Такеда Кемикал Индастриз, Лтд.	Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
CZ333698A3 (cs) *	1996-04-16	1999-01-13	Bayer Ag	D-mannitol a způsob jeho přípravy
JP3126683B2 (ja)	1996-04-16	2001-01-22	武田薬品工業株式会社	Ｄ−マンニトールおよびその製造法
PT907639E (pt) *	1996-06-24	2003-06-30	Novartis Ag	Compostos polimorficos
SE9603668D0 (sv) *	1996-10-08	1996-10-08	Astra Ab	Pharmaceutical compositions
SE9603667D0 (sv) *	1996-10-08	1996-10-08	Astra Ab	Pharmaceutical compositions
DE19725391A1 (de) *	1997-06-16	1998-12-17	Bayer Ag	Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
US6465477B1 (en) *	1997-08-18	2002-10-15	Kowa Company, Ltd.	Stable pharmaceutical composition
US8679534B2 (en) *	1997-12-12	2014-03-25	Andrx Labs, Llc	HMG-CoA reductase inhibitor extended release formulation
US6235311B1 (en) *	1998-03-18	2001-05-22	Bristol-Myers Squibb Company	Pharmaceutical composition containing a combination of a statin and aspirin and method
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
US5997905A (en) *	1998-09-04	1999-12-07	Mcneil-Ppc	Preparation of pharmaceutically active particles
SI20070A (sl) *	1998-09-18	2000-04-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Nove soli inhibitorjev HMG-CoA reduktaze
US20020169145A1 (en) *	1998-10-14	2002-11-14	Rajen Shah	Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
IL143197A0 (en)	1998-11-20	2002-04-21	Rtp Pharma Inc	Dispersible phospholipid stabilized microparticles
TWI230618B (en) *	1998-12-15	2005-04-11	Gilead Sciences Inc	Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
SI20109A (sl) *	1998-12-16	2000-06-30	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Stabilna farmacevtska formulacija
JP2002538202A (ja) *	1999-03-08	2002-11-12	メルクエンドカムパニーインコーポレーテッド	ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1036563A1 (fr) *	1999-03-08	2000-09-20	MERCK & CO. INC.	Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
AU4988100A (en) *	1999-05-07	2000-11-21	Brigham And Women's Hospital	Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US20020107173A1 (en) *	1999-11-04	2002-08-08	Lawrence Friedhoff	Method of treating amyloid beta precursor disorders
CA2389973A1 (fr) *	1999-11-04	2001-05-10	Andrx Corporation	Methode de traitement de troubles lies au precurseur beta-amyloide
GB0001621D0 (en) *	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
CA2398995C (fr)	2000-02-04	2014-09-23	Children's Hospital Research Foundation	Utilisation de lipase acide lysosomiale pour traiter l'atherosclerose et des maladies associees
DE60128683T2 (de) *	2000-04-11	2008-01-24	Sankyo Co., Ltd.	Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
GB0011163D0 (en) *	2000-05-10	2000-06-28	Astrazeneca Ab	Chemical compound
WO2001092223A1 (fr) *	2000-05-26	2001-12-06	Ciba Specialty Chemicals Holding Inc.	Processus de preparation de derives indole et d'intermediaires de ce processus
CZ20024015A3 (cs)	2000-06-09	2003-04-16	Lek Pharmaceutical D.D.	Stabilní farmaceutický produkt a jeho formulace
US6806290B2 (en)	2000-06-09	2004-10-19	Lek Pharmaceuticals D.D.	Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
WO2001093860A1 (fr) *	2000-06-09	2001-12-13	Lek Pharmaceuticals D.D.	Composition stabilisee pharmaceutiquement efficace et preparation pharmaceutique comprenant cette composition
US8586094B2 (en)	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
US7407484B2 (en)	2001-04-06	2008-08-05	Medic4All Inc.	Physiological monitoring system for a computational device of a human subject
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
GB0111077D0 (en)	2001-05-04	2001-06-27	Biochemie Gmbh	Organic compounds
WO2002096416A1 (fr) *	2001-05-31	2002-12-05	Cellegy Pharmaceuticals, Inc.	Inhibiteurs d'influx calcique active par reserve, et leurs procedes d'utilisation
EP1404301A4 (fr) *	2001-06-21	2006-03-22	Andrx Pharmaceuticals Inc	Compositions pharmaceutiques a liberation controlee, stables, contenant de la pravastatine
IL159861A0 (en) *	2001-08-03	2004-06-20	Ciba Sc Holding Ag	Crystalline forms of fluvastatin sodium
CA2463552C (fr)	2001-10-16	2011-05-17	Sloan-Kettering Institute For Cancer Research	Traitement des maladies neurodegeneratives et du cancer du cerveau
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
AP2004003112A0 (en) *	2002-02-14	2004-09-30	Ranbaxy Lab Ltd	Formulations of atorvastatin stabilised with alkali metal additions
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
AU2003213684C1 (en)	2002-03-04	2008-10-23	Merck Hdac Research, Llc	Methods of inducing terminal differentiation
US7148257B2 (en)	2002-03-04	2006-12-12	Merck Hdac Research, Llc	Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20050113577A1 (en) *	2002-04-16	2005-05-26	Karki Shyam B.	Solid forms of slats with tyrosine kinase activity
US7670769B2 (en)	2002-05-09	2010-03-02	The Brigham And Women's Hospital, Inc.	IL1RL-1 as a cardiovascular disease marker and therapeutic target
CA2385529A1 (fr) *	2002-05-21	2003-11-21	Bernard Charles Sherman	Formulations posologiques stables contenant de l'atorvastatin calcium
CA2486557A1 (fr) *	2002-06-13	2003-12-24	Novartis Ag	Sels de calcium de statines derivees d'indole
US20040006109A1 (en) *	2002-07-03	2004-01-08	Rajneesh Taneja	Liquid dosage forms of non-enterically coated acid-labile drugs
US20060019269A1 (en) *	2002-10-17	2006-01-26	Decode Genetics, Inc.	Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) *	2002-10-17	2008-11-27	Anna Helgadottir	Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20040198800A1 (en) *	2002-12-19	2004-10-07	Geoffrey Allan	Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
CA2510320C (fr)	2002-12-20	2012-10-09	St. James Associates Llc/Faber Research Series	Particules enrobees destinees a l'administration prolongee d'ingredients pharmaceutiques
ATE407670T1 (de)	2002-12-20	2008-09-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2519458A1 (fr) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Procede pour accroitre la biodisponibilite orale de s- 2-( '1-(2-ethylbutyl)cyclohexyl!carbonyl!amino)phenyl!-2-methylpropanethioate
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7166638B2 (en) *	2003-05-27	2007-01-23	Nicox S.A.	Statin derivatives
NZ577031A (en)	2003-05-30	2010-09-30	Ranbaxy Lab Ltd	Substituted pyrrole derivatives and their use as HMG-CO inhibitors
JP2007524619A (ja) *	2003-06-18	2007-08-30	テバファーマシューティカルインダストリーズリミティド	フルバスタチンナトリウム結晶型、その調製方法、これを含有する組成物、およびその使用法
JP2007077174A (ja) *	2003-06-25	2007-03-29	Novartis Ag	フルバスタチン含有錠剤
CA2529447A1 (fr) *	2003-06-25	2005-01-06	Novartis Ag	Comprime contenant de la fluvastatine et de la carmellose calcique
GB2404336A (en) *	2003-07-30	2005-02-02	Cipla Ltd	Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
AU2004266740B2 (en)	2003-08-21	2010-08-26	Merck Frosst Canada Ltd	Cathepsin cysteine protease inhibitors
EP1510208A1 (fr) *	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
US7829552B2 (en)	2003-11-19	2010-11-09	Metabasis Therapeutics, Inc.	Phosphorus-containing thyromimetics
EP1722780A4 (fr) *	2003-11-26	2008-12-17	Univ Duke	Technique de prevention ou de traitement du glaucome
EP1702626B1 (fr)	2003-12-30	2011-11-30	Kowa Company, Ltd.	Procédé de criblage d'inhibiteurs gamma-sécrétase
US8163797B2 (en) *	2003-12-31	2012-04-24	Actavis Elizabeth Llc	Method of treating with stable pravastatin formulation
US8158362B2 (en) *	2005-03-30	2012-04-17	Decode Genetics Ehf.	Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) *	2004-01-30	2010-08-26	Decode Genetics Ehf.	Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US7803838B2 (en) *	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
JP2008516890A (ja) *	2004-08-06	2008-05-22	トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド	新規なフェノフィブラート製剤および関連治療方法
US7642287B2 (en) *	2004-08-06	2010-01-05	Transform Pharmaceuticals, Inc.	Statin pharmaceutical compositions and related methods of treatment
US20090042979A1 (en) *	2004-08-06	2009-02-12	Transform Pharmaceuticals Inc.	Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
DE102004042139B4 (de) *	2004-08-31	2009-06-10	Aristocon Verwaltungs- Gmbh	Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
EP1809759B1 (fr)	2004-10-06	2013-09-11	The Brigham And Women's Hospital, Inc.	Pertinence de niveaux obtenus de marqueurs d'inflammation generalisee ala suite d'un traitement
ES2255426B1 (es)	2004-10-19	2007-08-16	Gp Pharm, S.A.	Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1827421B1 (fr)	2004-12-09	2017-09-27	Merck Sharp & Dohme Corp.	Modulateurs du recepteur de l'oestrogene
AU2005320547B2 (en)	2004-12-27	2009-02-05	Eisai R & D Management Co., Ltd.	Method for stabilizing anti-dementia drug
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
WO2006083779A2 (fr) *	2005-01-31	2006-08-10	Mylan Laboratories, Inc.	Metabolites de nebivolol hydroxyles
SI1855674T1 (sl)	2005-03-02	2014-10-30	Merck Sharp & Dohme Corp.	Sestavek za inhibicijo katepsina k
US20060229277A1 (en) *	2005-04-08	2006-10-12	Orbus Pharma, Inc.	Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
JP5597343B2 (ja) *	2005-04-28	2014-10-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬を含有する組成物
EP1888050B1 (fr)	2005-05-17	2012-03-21	Merck Sharp & Dohme Ltd.	Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
NZ563759A (en)	2005-05-31	2010-06-25	Mylan Lab Inc	Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
PL1919466T3 (pl)	2005-07-11	2012-05-31	Cortria Corp	Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
EP1940391A4 (fr) *	2005-08-05	2010-01-20	Orbus Pharma Inc	Compositions pharmaceutiques a liberation prolongee, stabilisees, comprenant un inhibiteur de l'hmg-coa reductase
PE20070427A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US8119358B2 (en)	2005-10-11	2012-02-21	Tethys Bioscience, Inc.	Diabetes-related biomarkers and methods of use thereof
WO2007054896A1 (fr)	2005-11-08	2007-05-18	Ranbaxy Laboratories Limited	Procede de preparation de sel hemicalcique d’acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
US20090247603A1 (en) *	2005-12-23	2009-10-01	Orbus Pharma, Inc.	Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
US20070202159A1 (en) *	2006-02-02	2007-08-30	Mathur Rajeev S	Pharmaceutical composition comprising stabilized statin particles
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
US20080033030A1 (en) *	2006-02-24	2008-02-07	Capua Simona D	Fluvastatin sodium pharmaceutical compositions
TW200744583A (en) *	2006-03-14	2007-12-16	Ranbaxy Lab Ltd	Statin stabilizing dosage formulations
PL2010528T3 (pl)	2006-04-19	2018-03-30	Novartis Ag	6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
WO2007146229A2 (fr)	2006-06-07	2007-12-21	Tethys Bioscience, Inc.	Marqueurs associés à des événements artério-vasculaires et procédés d'utilisation de ces marqueurs
ES2376396T3 (es)	2006-06-26	2012-03-13	Amgen Inc.	Método para tratar aterosclerosis.
ES2532595T3 (es) *	2006-08-30	2015-03-30	Kyushu University, National University Corporation	Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
EP2698157B1 (fr)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
PT3103448T (pt) *	2006-09-26	2019-07-12	Novartis Ag	Composições farmacêuticas que compreendem um modulador de s1p
EP1923053A1 (fr) *	2006-09-27	2008-05-21	Novartis AG	Composition pharmaceutique comprenant de la nilotinib ou son sel
EP1911441A3 (fr) *	2006-10-11	2008-08-06	Lupin Limited	Formule de dosage pharmaceutique à couleur stable et à libération contrôlée d'inhibiteurs de réductase HMG-COA, sans agents alcalisants ou tampons
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20110052688A1 (en) *	2006-11-21	2011-03-03	San-Laung Chow	Solid dispersion composition
WO2008064259A2 (fr) *	2006-11-21	2008-05-29	Biokey, Inc.	Composition de dispersion solide
EP2805945B1 (fr)	2007-01-10	2019-04-03	MSD Italia S.r.l.	Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase
ES2431163T3 (es)	2007-03-01	2013-11-25	Novartis Ag	Inhibidores de PIM quinasa y métodos para su uso
WO2008124121A1 (fr) *	2007-04-06	2008-10-16	Scidose, Llc	Polythérapie associant des statines et des 1,4-dihydropyridine-3,5-dicarboxydiesters et combinaisons de ceux-ci
US20080249156A1 (en) *	2007-04-09	2008-10-09	Palepu Nageswara R	Combinations of statins and anti-obesity agent and glitazones
US20080248115A1 (en) *	2007-04-09	2008-10-09	Palepu Nageswara R	Combinations of statins and anti-obesity agent
BRPI0810409A2 (pt)	2007-04-18	2015-02-18	Thethys Bioscience Inc	Biomarcadores relacionados ao diabetes e métodos de uso destes
ES2452349T3 (es)	2007-05-21	2014-04-01	Novartis Ag	Inhibidores de CSF-1R, composiciones, y métodos de uso
US8389553B2 (en)	2007-06-27	2013-03-05	Merck Sharp & Dohme Corp.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
MY159075A (en)	2007-07-26	2016-12-15	Amgen Inc	Modified lecithin-cholesterol acyltransferase enzymes
PT2222636E (pt)	2007-12-21	2013-07-16	Ligand Pharm Inc	Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
HUE035402T2 (en) *	2008-06-27	2018-05-02	Krka Tovarna Zdravil D D Novo Mesto	Pharmaceutical composition containing statin
EP2138165A1 (fr)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Composition pharmaceutique comportant de la statine
AU2008358622A1 (en) *	2008-06-27	2009-12-30	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Pharmaceutical compositions of rosuvastatin calcium
US20120046364A1 (en)	2009-02-10	2012-02-23	Metabasis Therapeutics, Inc.	Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
JP2012096998A (ja) *	2009-02-27	2012-05-24	Kowa Co	安定なカプセル製剤及びその製造方法
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
TR200904341A2 (tr)	2009-06-03	2010-12-21	Bi̇lgi̇ç Mahmut	Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2488028B1 (fr)	2009-10-14	2020-08-19	Merck Sharp & Dohme Corp.	Pipéridines substituées qui accroissent l'activité de p53 et utilisations de ces composés
US8632819B2 (en) *	2009-12-22	2014-01-21	Fmc Corporation	Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
CA2788571A1 (fr)	2010-02-01	2011-08-04	Andrew Redington	Conditionnement ischemique a distance pour traiter et prevenir la restenose
EP2552331B1 (fr)	2010-03-31	2020-01-08	The Hospital For Sick Children	Utilisation de conditionnement ischémique à distance pour améliorer l'évolution après un infarctus du myocarde
WO2011127341A2 (fr)	2010-04-08	2011-10-13	The Hospital For Sick Children	Utilisation du conditionnement ischémique à distance pour une lésion traumatique
US8372877B2 (en)	2010-04-16	2013-02-12	Cumberland Pharmaceuticals	Stabilized statin formulations
TR201009397A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Rosuvastatin içeren farmasötik bileşimler.
WO2011163330A1 (fr)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8609138B2 (en)	2010-06-30	2013-12-17	Mochida Pharmaceutical Co., Ltd.	ω3 fatty acid compound preparation
CN107090456B (zh)	2010-08-02	2022-01-18	瑟纳治疗公司	使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
SI2600851T1 (en)	2010-08-04	2018-07-31	Gruenenthal Gmbh	PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT
JP2013537423A (ja)	2010-08-17	2013-10-03	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012027331A1 (fr)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
WO2012030685A2 (fr)	2010-09-01	2012-03-08	Schering Corporation	Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP2615916B1 (fr)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
TW201219037A (en)	2010-10-06	2012-05-16	Univ Tokyo	Prophylactic and/or therapeutic agent against lymphedema
DK2632472T3 (en)	2010-10-29	2018-03-19	Sirna Therapeutics Inc	RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (fr)	2010-12-21	2012-06-28	Schering Corporation	Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012112363A1 (fr)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine protéases, les cathepsines
JP5988963B2 (ja)	2011-04-12	2016-09-07	沢井製薬株式会社	ピタバスタチン含有製剤及びその製造方法
EP2699568A1 (fr)	2011-04-21	2014-02-26	Piramal Enterprises Limited	Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
WO2012153181A1 (fr) *	2011-05-11	2012-11-15	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Composition pharmaceutique comprenant de la pitavastatine ou ses sels pharmaceutiquement acceptables
KR101830977B1 (ko) *	2011-06-30	2018-02-21	한미약품 주식회사	오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
WO2013063214A1 (fr)	2011-10-27	2013-05-02	Merck Sharp & Dohme Corp.	Nouveaux composés qui sont des inhibiteurs d'erk
CN104220460A (zh)	2011-12-08	2014-12-17	安姆根有限公司	激动人lcat抗原结合蛋白和它们在疗法中的用途
EP2844261B1 (fr)	2012-05-02	2018-10-17	Sirna Therapeutics, Inc.	Compositions de petit acide nucléique interférent (sina)
EP2879666B1 (fr)	2012-08-01	2020-04-08	Tavakoli, Zahra	Compositions congelées à écoulement libre comprenant un agent thérapeutique
EP3269362A1 (fr)	2012-08-08	2018-01-17	KOWA Co., Ltd.	Composition pharmaceutique comprenant de la pitavastatine
CN105050598B (zh)	2012-09-28	2018-04-27	默沙东公司	作为erk抑制剂的新型化合物
RS56680B1 (sr)	2012-11-28	2018-03-30	Merck Sharp & Dohme	Kompozicije i postupci za lečenje kancera
US8846657B2 (en)	2012-12-20	2014-09-30	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (fr)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
BR112015024234B1 (pt)	2013-03-21	2022-11-16	Eupraxia Pharmaceuticals USA LLC	Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
CN104069502B (zh) *	2013-03-29	2018-02-16	北京罗诺强施医药技术研发中心有限公司	复合骨架材料及其药物组合物
RO129060B1 (ro) *	2013-04-25	2014-11-28	Antibiotice S.A.	Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
KR101597004B1 (ko)	2013-07-25	2016-02-23	씨제이헬스케어 주식회사	서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3041938A1 (fr)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Polynucléotides circulaires
WO2015051479A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine-protéases de type cathepsines
EP3055314B1 (fr)	2013-10-08	2018-09-12	Merck Sharp & Dohme Corp.	Inhibiteurs de cysteine protease de type cathepsine
GB201319791D0 (en) *	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
US10441567B2 (en)	2014-01-17	2019-10-15	Ligand Pharmaceuticals Incorporated	Methods and compositions for modulating hormone levels
WO2015120580A1 (fr)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Inhibiteurs de protéases à cystéine de type cathépsines
WO2015185240A1 (fr)	2014-06-04	2015-12-10	Sigma-Tau Industrire Farmaceutiche Riunite S.P.A.	Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
CN107072997A (zh)	2014-11-11	2017-08-18	盐野义制药株式会社	含有对光不稳定的药物的多层片剂
ES2672993T3 (es)	2015-10-27	2018-06-19	Eupraxia Pharmaceuticals Inc.	Formulaciones de liberación sostenida de anestésicos locales
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
RU2648445C1 (ru) *	2016-11-03	2018-03-26	Светлана Асылхановна Астафьева	6-(3,3- диметил-3,4-дигидроизохинолин-1-ил) аминогексановая кислота и фармацевтическая композиция на ёе основе, обладающие анальгетической активностью
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
EP3706742B1 (fr)	2017-11-08	2023-03-15	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
KR101954568B1 (ko) *	2018-01-22	2019-03-05	한미약품 주식회사	오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
WO2020033285A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
EP3833668B1 (fr)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
EP3833667B1 (fr)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
CA3108388A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
MX2021012690A (es)	2019-04-19	2022-01-31	Ligand Pharm Inc	Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
JP7589247B2 (ja)	2019-12-17	2024-11-25	メルク・シャープ・アンド・ドーム・エルエルシー	Ｐｒｍｔ５阻害剤
EP4076460B1 (fr)	2019-12-17	2026-01-21	Merck Sharp & Dohme LLC	Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
WO2021126728A1 (fr)	2019-12-17	2021-06-24	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
WO2024180169A1 (fr)	2023-03-02	2024-09-06	Carcimun Biotech Gmbh	Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3865935A (en) *	1972-08-10	1975-02-11	Abbott Lab	Tableting of erythromycin base
US3952096A (en) *	1973-06-15	1976-04-20	Bristol-Myers Company	Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent
US3891755A (en) *	1973-07-11	1975-06-24	Abbott Lab	Dosage formulation for erythromycin cetyl sulfate
US4342767A (en) *	1980-01-23	1982-08-03	Merck & Co., Inc.	Hypocholesteremic fermentation products
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) *	1982-11-22	1988-03-03	Novartis Ag	Analogs of mevalolactone
US4744987A (en) *	1985-03-08	1988-05-17	Fmc Corporation	Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4671953A (en) *	1985-05-01	1987-06-09	University Of Utah Research Foundation	Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
DE3524572A1 (de) *	1985-07-10	1987-01-15	Thomae Gmbh Dr K	Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
CA1327010C (fr) *	1986-02-13	1994-02-15	Tadashi Makino	Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
GB2189699A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
US4929605A (en) *	1987-10-07	1990-05-29	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol derivatives
US5030447A (en) *	1988-03-31	1991-07-09	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions having good stability
US4997658A (en) *	1988-11-21	1991-03-05	Merck & Co., Inc.	Method for enhancing the lowering of plasma cholesterol levels
US4933165A (en) *	1989-01-18	1990-06-12	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US5004651A (en) *	1989-01-24	1991-04-02	Abbott Laboratories	Stabilizing system for solid dosage forms
CA2016467A1 (fr) *	1989-06-05	1990-12-05	Martin Eisman	Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
CA2042526A1 (fr) *	1990-06-11	1991-12-12	Adeoye Y. Olukotun	Methode permettant de prevenir une deuxieme crise cardiaque a l'aide d'un inhibiteur de la hmg coa-reductase

1992
- 1992-11-30 HU HU9203780A patent/HU217629B/hu unknown
- 1992-11-30 HU HU9203780A patent/HU9203780D0/hu unknown
- 1992-12-02 DE DE4240430A patent/DE4240430B4/de not_active Expired - Lifetime
- 1992-12-04 IT ITRM920870A patent/IT1256698B/it active IP Right Grant
- 1992-12-07 CH CH3751/92A patent/CH684309A5/de not_active IP Right Cessation
- 1992-12-08 DK DK92810962T patent/DK0547000T3/da active
- 1992-12-08 PT PT92810962T patent/PT547000E/pt unknown
- 1992-12-08 GB GB9225659A patent/GB2262229B/en not_active Expired - Lifetime
- 1992-12-08 EP EP92810962A patent/EP0547000B1/fr not_active Expired - Lifetime
- 1992-12-08 ES ES92810962T patent/ES2142819T3/es not_active Expired - Lifetime
- 1992-12-10 AU AU30069/92A patent/AU661075B2/en not_active Expired
- 1992-12-10 JP JP4352222A patent/JP2774037B2/ja not_active Expired - Lifetime
- 1992-12-10 IL IL10404192A patent/IL104041A/en not_active IP Right Cessation
- 1992-12-10 FI FI925615A patent/FI114284B/fi not_active IP Right Cessation
- 1992-12-10 CA CA002085037A patent/CA2085037C/fr not_active Expired - Lifetime
- 1992-12-10 SK SK3633-92A patent/SK281710B6/sk not_active IP Right Cessation
- 1992-12-10 CZ CS19923633A patent/CZ287776B6/cs not_active IP Right Cessation
- 1992-12-10 RO RO92-01545A patent/RO111542B1/ro unknown
- 1992-12-10 KR KR1019920023818A patent/KR100253824B1/ko not_active Expired - Lifetime
- 1992-12-10 NO NO924768A patent/NO302099B1/no not_active IP Right Cessation
- 1992-12-10 MX MX9207152A patent/MX9207152A/es unknown
- 1992-12-10 NZ NZ245421A patent/NZ245421A/en unknown
- 1992-12-11 ZA ZA929642A patent/ZA929642B/xx unknown
- 1992-12-11 RU RU92004564A patent/RU2121835C1/ru active
- 1992-12-11 AT AT0244992A patent/AT401870B/de not_active IP Right Cessation
- 1992-12-11 LU LU88201A patent/LU88201A1/fr unknown
- 1992-12-14 FR FR9215142A patent/FR2684876B1/fr not_active Expired - Lifetime
- 1992-12-22 US US07/995,252 patent/US5356896A/en not_active Expired - Lifetime
1993
- 1993-01-30 CN CN93100650A patent/CN1041794C/zh not_active Expired - Lifetime
1997
- 1997-03-06 HK HK25597A patent/HK25597A/xx not_active IP Right Cessation
- 1997-09-05 CY CY199497A patent/CY1994A/en unknown
2000
- 2000-03-10 GR GR20000400625T patent/GR3032929T3/el unknown

Also Published As

Publication number	Publication date
GR3032929T3 (en)	2000-07-31
SK363392A3 (en)	1994-11-09
LU88201A1 (fr)	1994-09-09
CZ363392A3 (en)	1993-09-15
HU217629B (hu)	2000-03-28
ITRM920870A0 (it)	1992-12-04
EP0547000B1 (fr)	2000-02-02
GB2262229A (en)	1993-06-16
KR100253824B1 (ko)	2000-05-01
JP2774037B2 (ja)	1998-07-09
JPH05246844A (ja)	1993-09-24
DE4240430A1 (fr)	1993-06-17
NO924768D0 (no)	1992-12-10
CH684309A5 (de)	1994-08-31
CN1041794C (zh)	1999-01-27
AU3006992A (en)	1993-06-17
MX9207152A (es)	1993-07-01
CA2085037C (fr)	2000-11-28
IT1256698B (it)	1995-12-12
ATA244992A (de)	1996-05-15
NO302099B1 (no)	1998-01-26
AU661075B2 (en)	1995-07-13
ES2142819T3 (es)	2000-05-01
US5356896A (en)	1994-10-18
RU2121835C1 (ru)	1998-11-20
GB9225659D0 (en)	1993-01-27
HK25597A (en)	1997-03-06
NZ245421A (en)	1995-11-27
FI925615A0 (fi)	1992-12-10
CA2085037A1 (fr)	1993-06-13
CZ287776B6 (cs)	2001-01-17
IL104041A0 (en)	1993-05-13
RO111542B1 (ro)	1996-11-29
ITRM920870A1 (it)	1994-06-04
NO924768L (no)	1993-06-14
FR2684876A1 (fr)	1993-06-18
CN1091634A (zh)	1994-09-07
FI925615L (fi)	1993-06-13
HU9203780D0 (en)	1993-03-29
EP0547000A1 (fr)	1993-06-16
PT547000E (pt)	2000-06-30
FI114284B (fi)	2004-09-30
ZA929642B (en)	1994-06-13
IL104041A (en)	1998-12-27
GB2262229B (en)	1995-11-01
HUT63328A (en)	1993-08-30
AT401870B (de)	1996-12-27
FR2684876B1 (fr)	1995-05-05
DE4240430B4 (de)	2007-12-27
SK281710B6 (sk)	2001-07-10
DK0547000T3 (da)	2000-06-26

Publication	Publication Date	Title
CA2085037C (fr)	2000-11-28	Compositions pharmaceutiques stabilisees contenant un compose inhibiteur de la hmg-coa reductase
KR100421347B1 (ko)	2004-03-06	약학 혼합 제제
US20050239884A1 (en)	2005-10-27	Compositions comprising hmg-coa reductase inhibitor
US5897877A (en)	1999-04-27	Oral pharmaceutical preparation containing erythromycin base
US20070218134A1 (en)	2007-09-20	Compositions Comprising Organic Compounds
EP1404301A2 (fr)	2004-04-07	Compositions pharmaceutiques a liberation controlee, stables, contenant de la pravastatine
NZ270729A (en)	1995-11-27	Fluvastatin sodium in an alkaline carrier
US20040180087A1 (en)	2004-09-16	Stable controlled release pharmaceutical compositions containing pravastatin
US20190070167A1 (en)	2019-03-07	Pitavastatin containing preparation and method for producing same
AU2002312297A1 (en)	2003-01-08	Stable controlled release pharmaceutical compositions containing pravastatin